CN103608004A - 用于治疗注意力缺陷障碍的方法和组合物 - Google Patents

用于治疗注意力缺陷障碍的方法和组合物 Download PDF

Info

Publication number
CN103608004A
CN103608004A CN201280024451.8A CN201280024451A CN103608004A CN 103608004 A CN103608004 A CN 103608004A CN 201280024451 A CN201280024451 A CN 201280024451A CN 103608004 A CN103608004 A CN 103608004A
Authority
CN
China
Prior art keywords
hours
pharmaceutical composition
solid oral
oral pharmaceutical
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280024451.8A
Other languages
English (en)
Chinese (zh)
Inventor
D·李克里施
F·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ironshore Pharmaceuticals and Development Inc Cayman Island
Original Assignee
Ironshore Pharmaceuticals and Development Inc Cayman Island
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironshore Pharmaceuticals and Development Inc Cayman Island filed Critical Ironshore Pharmaceuticals and Development Inc Cayman Island
Priority to CN201910483969.1A priority Critical patent/CN110151731A/zh
Publication of CN103608004A publication Critical patent/CN103608004A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280024451.8A 2011-03-23 2012-03-23 用于治疗注意力缺陷障碍的方法和组合物 Pending CN103608004A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910483969.1A CN110151731A (zh) 2011-03-23 2012-03-23 用于治疗注意力缺陷障碍的方法和组合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161466684P 2011-03-23 2011-03-23
US61/466,684 2011-03-23
US201161561763P 2011-11-18 2011-11-18
US61/561,763 2011-11-18
US201261591129P 2012-01-26 2012-01-26
US61/591,129 2012-01-26
PCT/US2012/030472 WO2012129551A1 (en) 2011-03-23 2012-03-23 Methods and compositions for treatment of attention deficit disorder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910483969.1A Division CN110151731A (zh) 2011-03-23 2012-03-23 用于治疗注意力缺陷障碍的方法和组合物

Publications (1)

Publication Number Publication Date
CN103608004A true CN103608004A (zh) 2014-02-26

Family

ID=46879766

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280024451.8A Pending CN103608004A (zh) 2011-03-23 2012-03-23 用于治疗注意力缺陷障碍的方法和组合物
CN201910483969.1A Pending CN110151731A (zh) 2011-03-23 2012-03-23 用于治疗注意力缺陷障碍的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910483969.1A Pending CN110151731A (zh) 2011-03-23 2012-03-23 用于治疗注意力缺陷障碍的方法和组合物

Country Status (15)

Country Link
US (1) US9028868B2 (https=)
EP (4) EP4011364B1 (https=)
JP (8) JP6043785B2 (https=)
KR (2) KR20160135373A (https=)
CN (2) CN103608004A (https=)
AU (3) AU2012230733B2 (https=)
BR (1) BR112013024401B1 (https=)
CA (1) CA2830788C (https=)
DK (3) DK4011364T3 (https=)
ES (3) ES2883589T3 (https=)
MX (4) MX357551B (https=)
PT (3) PT4011364T (https=)
SG (2) SG10201901167SA (https=)
WO (1) WO2012129551A1 (https=)
ZA (1) ZA201307649B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109414435A (zh) * 2016-05-26 2019-03-01 奥维德医疗公司 使用哌苯甲醇治疗行为综合征的方法
CN109475505A (zh) * 2016-07-06 2019-03-15 度瑞公司 具有药物组成物、屏障层及药物层的口服剂型
TWI747810B (zh) * 2014-10-31 2021-12-01 加拿大商普渡製藥公司 特別用於治療注意力缺失症之方法及組成物
CN113891713A (zh) * 2019-01-25 2022-01-04 艾伦索尔医药发展股份有限公司 用于治疗注意力缺陷多动障碍的哌甲酯组合物

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241391B2 (en) * 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) * 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) * 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) * 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) * 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
GB201319791D0 (en) * 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
KR102790656B1 (ko) * 2015-05-04 2025-04-02 컨플루언스 파마슈티컬스, 엘엘씨 아캄프로세이트의 스프링클 제형
US12472149B2 (en) 2015-07-17 2025-11-18 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
FI3324948T3 (fi) * 2015-07-17 2023-05-05 Be Pharbel Mfg Monikerroksisia farmaseuttisesti aktiivista yhdistettä vapauttavia mikropartikkeleita nestemäisessä annosmuodossa
US10383825B2 (en) 2015-08-13 2019-08-20 Temple University—Of the Commonwealth System of Higher Education Calcium alginate dosage formulations, and methods of making and using thereof
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
WO2017173068A1 (en) * 2016-03-30 2017-10-05 University Of Maryland, Baltimore Microparticulate system for colonic drug delivery
US9931303B1 (en) 2017-02-06 2018-04-03 Alcobra Ltd. Abuse deterrent formulations of amphetamine
US20180256515A1 (en) * 2017-03-10 2018-09-13 Adare Pharmaceuticals, Inc. Oral amphetamine composition
JP7172997B2 (ja) * 2017-04-28 2022-11-16 アステラス製薬株式会社 エンザルタミドを含有する経口投与用医薬組成物
IL270654B2 (en) * 2017-05-17 2024-07-01 Confluence Pharmaceuticals Llc Formulations of homotaurines and salts thereof
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP3459528B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
CN108653243B (zh) * 2018-03-30 2019-03-22 江苏南农高科动物药业有限公司 一种缓释替米考星微囊粉的制备方法
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662901B1 (en) 2018-12-07 2025-01-01 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
WO2000023055A1 (en) * 1998-10-21 2000-04-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
CN1684668A (zh) * 2002-09-24 2005-10-19 希拉实验室股份有限公司 安非他明盐的缓释传递
US20070264323A1 (en) * 2006-05-12 2007-11-15 Shire Llc Controlled dose drug delivery system
CN101277684A (zh) * 2005-09-30 2008-10-01 弗拉梅技术公司 至少一种活性成分改善释放的微粒及含有该微粒的口服药物剂型

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8322007D0 (en) 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4904476A (en) 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
AU629915B2 (en) 1989-02-16 1992-10-15 British Technology Group Limited Dispensing device
JP2558396B2 (ja) 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
JP2916978B2 (ja) 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
US5658590A (en) 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
IT1276689B1 (it) 1995-06-09 1997-11-03 Applied Pharma Res Forma farmaceutica solida ad uso orale
GB9514451D0 (en) 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US6355656B1 (en) 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5922736A (en) 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
MX9805870A (https=) 1996-01-22 1999-01-31
KR100453707B1 (ko) 1996-02-02 2005-01-25 메디바 유럽 리미티드 디-트레오-(알,알)-메틸페니데이트의제조방법및에피머화에의한불필요한거울상이성질체의재순환방법
ES2173422T3 (es) 1996-03-08 2002-10-16 Medeva Europ Ltd Disociacion de treo-metilfenidato.
GB9606417D0 (en) 1996-03-27 1996-06-05 Chiroscience Ltd Asymmetric cyclisation
CA2264852C (en) 1996-09-30 2005-11-01 Alza Corporation Use of methylphenidate or a pharmaceutically acceptable salt thereof
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
EP1782798A3 (en) 1996-11-25 2008-05-21 Alza Corporation Ascending-dose dosage form
PT946151E (pt) 1996-11-25 2006-07-31 Alza Corp Forma de dosagem de dose crescente
WO1998025902A1 (en) 1996-12-13 1998-06-18 Medeva Europe Limited The preparation of enantiomerically-enriched threo-methylphenidate
GB9700912D0 (en) 1997-01-17 1997-03-05 Chiroscience Ltd Resolution
US6210705B1 (en) 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
EP2266542A3 (en) * 1998-10-01 2013-07-31 Elan Pharma International Limited Controlled release nanoparticulate compositions
MXPA01004381A (es) 1998-11-02 2005-09-08 Elan Corp Plc Composicion de multiparticulado de liberacion modificada.
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6384020B1 (en) 1999-07-14 2002-05-07 Shire Laboratories, Inc. Rapid immediate release oral dosage form
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
GB9918735D0 (en) * 1999-08-09 1999-10-13 Straken Limited Transdermal patches
US6898455B2 (en) 1999-10-29 2005-05-24 The Mclean Hospital Corporation Method for providing optimal drug dosage
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US6569456B2 (en) 2000-01-13 2003-05-27 Osmotica Corp. Osmotic device containing diltiazem and an ACE inhibitor or diuretic
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6520921B1 (en) 2000-06-20 2003-02-18 Eastman Kodak Company Method for determining attention deficit hyperactivity disorder (ADHD) medication dosage and for monitoring the effects of (ADHD) medication
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US20030232890A1 (en) 2000-11-01 2003-12-18 Sention, Inc. Methods for treating an impairment in memory consolidation
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20040137062A1 (en) 2001-05-25 2004-07-15 Sham Chopra Chronotherapy tablet and methods related thereto
JP4426286B2 (ja) * 2001-07-10 2010-03-03 テバ ファーマシューティカル インダストリーズ リミティド ０次、０次−二相性、上昇型又は下降型薬物放出のための薬物送達システム
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US6811794B2 (en) 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7105486B2 (en) 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US6726624B2 (en) 2002-03-06 2004-04-27 The Mclean Hospital Corporation Method and apparatus for determining attention deficit hyperactivity disorder (adhd) medication dosage and for monitoring the effects of adhd medication on people who have adhd using complementary tests
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
JP2006501261A (ja) 2002-09-09 2006-01-12 バイオヴェイル ラボラトリーズ インコーポレイテッド 時間治療用ジルチアゼム製剤およびその投与
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
EP1589951B1 (en) 2003-01-03 2017-08-09 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
SI1644019T2 (en) 2003-05-29 2018-04-30 Shire Llc Abuse resistant amphetamine compounds
US20050031688A1 (en) 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
DE602005005167T2 (de) 2004-01-29 2009-04-30 Pfizer Inc. 1-isopropyl-2-oxo-1,2-dihydropyridin-3-carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
ES2261006B1 (es) * 2004-06-10 2007-11-01 Laboratorios Rubio, S.A. Pellet multicapa de liberacion controlada de metilfenidato.
US20070036843A1 (en) * 2005-01-28 2007-02-15 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
FR2892937B1 (fr) * 2005-11-10 2013-04-05 Flamel Tech Sa Forme pharmaceutique orale microparticulaire anti-mesusage
MX350380B (es) 2006-05-09 2017-09-05 SpecGx LLC Formas de dosificacion solida de liberacion modificada en el orden de cero.
ES2529455T3 (es) * 2006-05-12 2015-02-20 Shire Llc Sistema de administración de fármacos por dosis controladas
FR2901478B1 (fr) * 2006-05-24 2015-06-05 Flamel Tech Sa Forme pharmaceutique orale multimicroparticulaire a liberation prolongee
CN1985810A (zh) * 2006-07-28 2007-06-27 中国人民解放军第二军医大学 盐酸哌甲酯缓控释胶囊及其制备方法
KR100888131B1 (ko) 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
US8642083B2 (en) 2006-10-30 2014-02-04 Hanall Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
ES2393814T3 (es) 2007-04-04 2012-12-28 Sigmoid Pharma Limited Una composición farmacéutica oral
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
CA2713128C (en) * 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
CA2627198A1 (en) 2008-03-27 2009-09-27 Pharmascience Inc. Methylphenidate extended release therapeutic drug delivery system
AU2010300641B2 (en) 2009-09-30 2016-03-17 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
WO2000023055A1 (en) * 1998-10-21 2000-04-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
CN1684668A (zh) * 2002-09-24 2005-10-19 希拉实验室股份有限公司 安非他明盐的缓释传递
CN101277684A (zh) * 2005-09-30 2008-10-01 弗拉梅技术公司 至少一种活性成分改善释放的微粒及含有该微粒的口服药物剂型
US20070264323A1 (en) * 2006-05-12 2007-11-15 Shire Llc Controlled dose drug delivery system

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI747810B (zh) * 2014-10-31 2021-12-01 加拿大商普渡製藥公司 特別用於治療注意力缺失症之方法及組成物
CN109414435A (zh) * 2016-05-26 2019-03-01 奥维德医疗公司 使用哌苯甲醇治疗行为综合征的方法
CN109475505A (zh) * 2016-07-06 2019-03-15 度瑞公司 具有药物组成物、屏障层及药物层的口服剂型
CN113891713A (zh) * 2019-01-25 2022-01-04 艾伦索尔医药发展股份有限公司 用于治疗注意力缺陷多动障碍的哌甲酯组合物

Also Published As

Publication number Publication date
BR112013024401B1 (pt) 2022-01-11
JP2017128614A (ja) 2017-07-27
JP2024019726A (ja) 2024-02-09
JP2020079322A (ja) 2020-05-28
JP2014508812A (ja) 2014-04-10
EP4316488A3 (en) 2024-02-28
EP4011364B1 (en) 2023-12-13
JP6325148B2 (ja) 2018-05-16
AU2016228307A1 (en) 2016-10-06
EP2688557A4 (en) 2014-09-24
DK3272342T3 (da) 2021-06-07
DK4011364T3 (da) 2024-03-18
EP4316488A2 (en) 2024-02-07
MX383127B (es) 2025-03-13
US9028868B2 (en) 2015-05-12
JP6043785B2 (ja) 2016-12-14
KR101834033B1 (ko) 2018-04-13
ES2973539T3 (es) 2024-06-20
JP2022066315A (ja) 2022-04-28
AU2012230733B2 (en) 2016-10-20
WO2012129551A1 (en) 2012-09-27
JP2016117767A (ja) 2016-06-30
CA2830788C (en) 2016-05-17
AU2012230733A1 (en) 2013-10-17
ES2644942T3 (es) 2017-12-01
MX2021000431A (es) 2022-10-28
JP2026063249A (ja) 2026-04-10
PT4011364T (pt) 2024-02-07
DK2688557T3 (da) 2017-11-27
SG10201901167SA (en) 2019-03-28
BR112013024401A2 (pt) 2017-11-07
AU2018202002A1 (en) 2018-04-12
EP2688557A1 (en) 2014-01-29
EP3272342A1 (en) 2018-01-24
MX2022013590A (es) 2022-11-16
EP3272342B1 (en) 2021-05-26
JP2018197276A (ja) 2018-12-13
US20120276017A1 (en) 2012-11-01
PT3272342T (pt) 2021-07-12
AU2018202002B2 (en) 2019-04-04
PT2688557T (pt) 2017-11-23
EP2688557B1 (en) 2017-08-23
MX357551B (es) 2018-07-13
KR20140030158A (ko) 2014-03-11
KR20160135373A (ko) 2016-11-25
EP4011364A1 (en) 2022-06-15
SG193587A1 (en) 2013-10-30
ZA201307649B (en) 2014-06-25
MX2013010920A (es) 2014-08-29
CA2830788A1 (en) 2012-09-27
CN110151731A (zh) 2019-08-23
ES2883589T3 (es) 2021-12-09

Similar Documents

Publication Publication Date Title
AU2018202002B2 (en) Methods and compositions for treatment of attention deficit disorder
US9023389B1 (en) Compositions for treatment of attention deficit hyperactivity disorder
US9511032B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
US9034902B2 (en) Methods for treatment of attention deficit hyperactivity disorder
HK40107582A (en) Methods and compositions for treatment of attention deficit disorder
HK40073671B (en) Methods and compositions for treatment of attention deficit disorder
HK40073671A (en) Methods and compositions for treatment of attention deficit disorder

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140226

RJ01 Rejection of invention patent application after publication